Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 in Systemic Myasthenia Gravis
NCT04302103Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in myasthenia gravis (MG), sponsored by RemeGen. Started Jul 2020; status: completed.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04302103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302103.